Trastuzumab, in combination with chemotherapy as adjuvant therapy in HER2+ early-stage breast cancer, is widely recommended due to its effectiveness in increasing overall survival and disease-free survival [8]. This evidence concerns the gene ERBB2 and breast carcinoma.